IBDEI31N ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,51030,1,3,0)
 ;;=3^Polymyalgia rheumatica
 ;;^UTILITY(U,$J,358.3,51030,1,4,0)
 ;;=4^M35.3
 ;;^UTILITY(U,$J,358.3,51030,2)
 ;;=^96292
 ;;^UTILITY(U,$J,358.3,51031,0)
 ;;=M33.20^^222^2466^203
 ;;^UTILITY(U,$J,358.3,51031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51031,1,3,0)
 ;;=3^Polymyositis, organ involvement unspec
 ;;^UTILITY(U,$J,358.3,51031,1,4,0)
 ;;=4^M33.20
 ;;^UTILITY(U,$J,358.3,51031,2)
 ;;=^5011770
 ;;^UTILITY(U,$J,358.3,51032,0)
 ;;=M34.0^^222^2466^206
 ;;^UTILITY(U,$J,358.3,51032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51032,1,3,0)
 ;;=3^Progressive systemic sclerosis
 ;;^UTILITY(U,$J,358.3,51032,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,51032,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,51033,0)
 ;;=E20.1^^222^2466^207
 ;;^UTILITY(U,$J,358.3,51033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51033,1,3,0)
 ;;=3^Pseudohypoparathyroidism
 ;;^UTILITY(U,$J,358.3,51033,1,4,0)
 ;;=4^E20.1
 ;;^UTILITY(U,$J,358.3,51033,2)
 ;;=^100160
 ;;^UTILITY(U,$J,358.3,51034,0)
 ;;=L40.54^^222^2466^209
 ;;^UTILITY(U,$J,358.3,51034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51034,1,3,0)
 ;;=3^Psoriatic juvenile arthropathy
 ;;^UTILITY(U,$J,358.3,51034,1,4,0)
 ;;=4^L40.54
 ;;^UTILITY(U,$J,358.3,51034,2)
 ;;=^5009169
 ;;^UTILITY(U,$J,358.3,51035,0)
 ;;=I73.00^^222^2466^213
 ;;^UTILITY(U,$J,358.3,51035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51035,1,3,0)
 ;;=3^Raynaud's syndrome w/o gangrene
 ;;^UTILITY(U,$J,358.3,51035,1,4,0)
 ;;=4^I73.00
 ;;^UTILITY(U,$J,358.3,51035,2)
 ;;=^5007796
 ;;^UTILITY(U,$J,358.3,51036,0)
 ;;=N13.5^^222^2466^99
 ;;^UTILITY(U,$J,358.3,51036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51036,1,3,0)
 ;;=3^Crosng vessel & strict of ureter w/o hydronephr
 ;;^UTILITY(U,$J,358.3,51036,1,4,0)
 ;;=4^N13.5
 ;;^UTILITY(U,$J,358.3,51036,2)
 ;;=^5015580
 ;;^UTILITY(U,$J,358.3,51037,0)
 ;;=N13.6^^222^2466^210
 ;;^UTILITY(U,$J,358.3,51037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51037,1,3,0)
 ;;=3^Pyonephrosis
 ;;^UTILITY(U,$J,358.3,51037,1,4,0)
 ;;=4^N13.6
 ;;^UTILITY(U,$J,358.3,51037,2)
 ;;=^101552
 ;;^UTILITY(U,$J,358.3,51038,0)
 ;;=M06.9^^222^2466^214
 ;;^UTILITY(U,$J,358.3,51038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51038,1,3,0)
 ;;=3^Rheumatoid arthritis, unspec
 ;;^UTILITY(U,$J,358.3,51038,1,4,0)
 ;;=4^M06.9
 ;;^UTILITY(U,$J,358.3,51038,2)
 ;;=^5010145
 ;;^UTILITY(U,$J,358.3,51039,0)
 ;;=M35.01^^222^2466^225
 ;;^UTILITY(U,$J,358.3,51039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51039,1,3,0)
 ;;=3^Sicca syndrome w/ keratoconjunctivitis
 ;;^UTILITY(U,$J,358.3,51039,1,4,0)
 ;;=4^M35.01
 ;;^UTILITY(U,$J,358.3,51039,2)
 ;;=^5011787
 ;;^UTILITY(U,$J,358.3,51040,0)
 ;;=M35.00^^222^2466^226
 ;;^UTILITY(U,$J,358.3,51040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51040,1,3,0)
 ;;=3^Sicca syndrome, unspec
 ;;^UTILITY(U,$J,358.3,51040,1,4,0)
 ;;=4^M35.00
 ;;^UTILITY(U,$J,358.3,51040,2)
 ;;=^5011786
 ;;^UTILITY(U,$J,358.3,51041,0)
 ;;=M35.9^^222^2466^280
 ;;^UTILITY(U,$J,358.3,51041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51041,1,3,0)
 ;;=3^Systemic invlmnt of conn tiss, unspec
 ;;^UTILITY(U,$J,358.3,51041,1,4,0)
 ;;=4^M35.9
 ;;^UTILITY(U,$J,358.3,51041,2)
 ;;=^5011797
 ;;^UTILITY(U,$J,358.3,51042,0)
 ;;=M32.10^^222^2466^282
 ;;^UTILITY(U,$J,358.3,51042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,51042,1,3,0)
 ;;=3^Systemic lupus erythem, organ/syst involv, unspec
 ;;^UTILITY(U,$J,358.3,51042,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,51042,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,51043,0)
 ;;=M34.9^^222^2466^283
 ;;^UTILITY(U,$J,358.3,51043,1,0)
 ;;=^358.31IA^4^2
